Welcher MS-Patient braucht was?

Okuda, D.T., et al., Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology, 2009. 72(9): p. 800–5.

Leray, E., et al., Evidence for a two-stage disability progression in multiple sclerosis. Brain, 2010. 133(Pt 7): p. 1900–13.

Trapp, B.D., et al., Axonal transection in the lesions of multiple sclerosis. N Engl J Med, 1998. 338(5): p. 278–85.

De Stefano, N., et al., Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol, 2001. 58(1): p. 65–70.

Linker, R., et al., [„Time is brain“ in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy]. Nervenarzt, 2015. 86(12): p. 1528–37.

Kappos, L., et al., Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2006. 67(7): p. 1242–9.

Comi, G., et al., Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, 2001. 357(9268): p. 1576–82.

Jacobs, L.D., et al., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med, 2000. 343(13): p. 898–904.

Comi, G., et al., Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, 2009. 374(9700): p. 1503–11.

McDonald, W.I., et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol, 2001. 50(1): p. 121–7.

Filippi, M., et al., MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol, 2016. 15(3): p. 292–303.

Moraal, B., et al., Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol, 2009. 66(11): p. 1345–52.

EMA, EPAR Summary for the public - fingolimod. 2016, European Medicines Agency.

http://www.kompetenznetz-multiplesklerose.de/de/basistherapie . 2016.

http://www.kompetenznetz-multiplesklerose.de/images/stories/PDF_Dateien/Leitlinie/dgn-kknms_ms-ll_20140813.pdf . 2014.

Havrdova, E., et al., Freedom from disease activity in multiple sclerosis. Neurology, 2010. 74 Suppl 3: p. S3–7.

Rotstein, D.L., et al., Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol, 2015. 72(2): p. 152–8.

Stangel, M., et al., Towards the implementation of ‚no evidence of disease activity‘ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord, 2015. 8(1): p. 3–13.

Kieseier, B.C., The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs, 2011. 25(6): p. 491–502.

Oh, J. and P.A. Calabresi, Emerging injectable therapies for multiple sclerosis. The Lancet Neurology, 2013. 12(11): p. 1115–1126.

BfArM. Sicherheitsrelevante Informationen zu Beta-Interferonen: Risiko einer thrombotischen Mikroangiopathie sowie eines nephrotischen Syndroms. 2014 [cited; Available from: http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2014/info-interferon-beta.html .

Reder, A.T., et al., Short-term and long-term safety and tolerability of interferon beta-1b in multiple sclerosis. Mult Scler Relat Disord, 2014. 3(3): p. 294–302.

Farina, C., et al., Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol, 2005. 4(9): p. 567–75.

Comi, G., M. Filippi, and J.S. Wolinsky, European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol, 2001. 49(3): p. 290–7.

Johnson, K.P., et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995. 45(7): p. 1268–76.

Khan, O., et al., Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol, 2013. 73(6): p. 705–13.

O’Connor, P., et al., Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med, 2011. 365(14): p. 1293–303.

Confavreux, C., et al., Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol, 2014. 13(3): p. 247–56.

Vermersch, P., et al., Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler, 2014. 20(6): p. 705–16.

O’Connor, P., et al., Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology, 2016. 86(10): p. 920–30.

Schimrigk, S., et al., Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol, 2006. 13(6): p. 604–10.

Gold, R., et al., Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med, 2012. 367(12): p. 1098–107.

Fox, R.J., et al., Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med, 2012. 367(12): p. 1087–97.

BfArM. Rote-Hand-Brief zu Tecfidera® (Dimethylfumarat): Neue Maßnahmen zur Senkung des Risikos einer progressiven multifokalen Leukenzephalopathie (PML) - vermehrte Überwachung und Absetzen der Therapie. 2015 [cited; Available from: http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2015/rhb-tecfidera.html .

Gold, R., et al., Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet, 2013. 381(9884): p. 2167–75.

Kappos, L., et al., Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med, 2015. 373(15): p. 1418–28.

Ontaneda, D. and J.A. Cohen, Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Rev Clin Pharmacol, 2011. 4(5): p. 567–70.

Kappos, L., et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med, 2010. 362(5): p. 387–401.

Cohen, J.A., et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med, 2010. 362(5): p. 402–15.

Cohen, J.A., et al., Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry, 2016. 87(5): p. 468–75.

BfArM. Rote-Hand-Brief zu Fingolimod (Gilenya®): Risiken im Zusammenhang mit den Auswirkungen auf das Immunsystem. 2016 [cited; Available from: http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2016/rhb-gilenya.html .

Kappos, L., et al., Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurol, 2016. 73(9): p. 1089–98.

Kappos, L., et al., Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol, 2016. 15(11): p. 1148–59.

Cohen, J.A., et al., Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, 2012. 380(9856): p. 1819–28.

Coles, A.J., et al., Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, 2012. 380(9856): p. 1829–39.

Tuohy, O., et al., Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry, 2015. 86(2): p. 208–15.

Polman, C.H., et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 2006. 354(9): p. 899–910.

Rudick, R.A., et al., Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med, 2006. 354(9): p. 911–23.

Paul-Ehrlich-Institut. Natalizumab (TYSABRI ): Aktualisierung der Maßnahmen zur Minimierung des PML-Risikos. 2016 [cited; Available from: http://www.pei.de/DE/arzneimittelsicherheit-vigilanz/pharmakovigilanz/rote-hand-briefe/rote-hand-briefe-node.html .

Coles, A.J., et al., Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, 2012. 380(9856): p. 1829–39.

Panitch, H., et al., Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology, 2002. 59(10): p. 1496–506.

http://www.msbase.org .

Spelman, T., et al., Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Eur J Neurol, 2016. 23(4): p. 729–36.

Kalincik, T., et al., Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol, 2014. 77(3): p. 425–35.

Ziemssen, T., R. Kern, and C. Cornelissen, The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol, 2015. 15: p. 93.

Heesen, C., et al., Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report. Mult Scler, 2014. 20(13): p. 1795–8.

Lu, E., et al., Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology, 2012. 79(11): p. 1130–5.

Herbstritt, S., et al., Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler, 2016. 22(6): p. 810–6.